Dendreon reported a net quarterly loss of $17.3 million, down from $19.8 million for the same period last year.

Share story

Dendreon reported a net quarterly loss of $17.3 million, down from $19.8 million for the same period last year. The Seattle-based biotech company said Friday it had lower operating costs than last year, but losses included a non-cash charge of $9.1 million that reflected the increase in value of warrants issued in April.

The company, which aims to launch a prostate cancer drug known as Provenge, said it had $107 million in cash and short-term investments at the end of the quarter, down from $121 million at the end of 2007.

Dendreon also said it had withdrawn a net amount of $20 million from its equity line of credit.